Objective The objective is to provide guidelines for the use of antenatal magnesium sulphate
for fetal neuroprotection of the preterm infant. Options Antenatal magnesium sulphate …

Background Magnesium sulphate is a common therapy in perinatal care. Its benefits when
given to women at risk of preterm birth for fetal neuroprotection (prevention of cerebral palsy …

Background It is important to establish whether research recommendations regarding
magnesium sulphate for neuroprotection can be readily translated into clinical practice and …

Background Magnesium sulphate is extensively used in obstetrics for the treatment and
prevention of eclampsia. A recent meta‐analysis has shown that magnesium sulphate is an …

Background Babies born preterm are at an increased risk of dying in the first weeks of life,
and those who survive have a higher rate of cerebral palsy (CP) compared with babies born …

Objective: To provide guidelines for the use of antenatal magnesium sulphate (MgSO4) for
fetal neuroprotection of the preterm infant. Options: Antenatal MgSO4 administration should …

Despite improvements in perinatal care, preterm birth still occurs regularly and the
associated brain injury and adverse neurological outcomes remain a persistent challenge …

Background Magnesium sulfate is an accepted intervention for fetal neuroprotection. There
are some perceived differences in the international recommendations on the use …

Available evidence now suggests that magnesium sulfate administered to mothers prior to
early preterm delivery reduces the risk of cerebral palsy in surviving neonates. The …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …